# Vor Bio To Participate in Upcoming September Conferences
Canonical URL: https://biopharmsignal.com/news/VOR/vor-bio-to-participate-in-upcoming-september-conferences-95d95093
Ticker: VOR
Company: Vor Biopharma
Source: Vor Biopharma
Published: 2026-09-01 12:00 EST
## Summary

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune...

## Article Body
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences:

Wells Fargo 21st Annual Healthcare Conference

Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET

Citi’s 2026 Biopharma Back to School Conference

Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9th Presentation Time: 11:20AM ET

Morgan Stanley 24th Annual Global Healthcare Conference

Forum: 1x1 Meetings Date: Monday, September 14th

Baird’s 2026 Global Healthcare Conference

Forum: Presentation and 1x1 Meetings Date: Tuesday, September 15th Presentation Time: 9:05AM ET

Stifel’s 2026 Virtual Immunology and Inflammation Forum

Forum: Presentation and 1x1 Meetings Date: Wednesday, September 23rd Presentation Time: 11:30AM ET

A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.

About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com . Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.
## Recent Company News
- 2026-09-08 11:00 EST — [Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis](https://biopharmsignal.com/news/VOR/vor-completes-enrollment-of-global-phase-3-upstream-mg-trial-and-expands-telitac-746ad67c) — Source: Vor Biopharma
- 2026-09-04 20:05 EST — [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-312d9743) — Source: Vor Biopharma
- 2026-09-01 12:00 EST — [Vor Bio To Participate in Upcoming September Conferences](https://biopharmsignal.com/news/VOR/vor-bio-to-participate-in-upcoming-september-conferences-95d95093) — Source: Vor Biopharma
- 2026-08-11 13:30 EST — [Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VOR/vor-bio-reports-second-quarter-2026-financial-results-and-provides-corporate-upd-82ef6835) — Source: Vor Biopharma
- 2026-07-07 20:01 EST — [Vor Bio Appoints David Zaccardelli to Board of Directors](https://biopharmsignal.com/news/VOR/vor-bio-appoints-david-zaccardelli-to-board-of-directors-7c744ed5) — Source: Vor Biopharma
## Related News
- 2026-09-09 23:25 EST — IRON — [Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-718b0075)
- 2026-09-09 20:17 EST — COO — [CooperCompanies Announces Third Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-third-quarter-2026-results-0256684b)
- 2026-09-09 20:15 EST — COO — [CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization](https://biopharmsignal.com/news/COO/coopercompanies-completes-strategic-review-increases-share-repurchase-authorizat-c3b7ff3b)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment](https://biopharmsignal.com/news/NBTX/nanobiotix-participera-la-conf-rence-h-c-wainwright-28th-annual-global-investmen-8b1208fb)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/NBTX/nanobiotix-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-co-bd8b771d)